RT Journal Article
T1 A compendium answering 150 questions on COVID-19 and SARS-CoV-2.
A1 Riggioni, Carmen
A1 Comberiati, Pasquale
A1 Giovannini, Mattia
A1 Agache, Ioana
A1 Akdis, Mübeccel
A1 Alves-Correia, Magna
A1 Anto, Josep M
A1 Arcolaci, Alessandra
A1 Azkur, Ahmet Kursat
A1 Azkur, Dilek
A1 Beken, Burcin
A1 Boccabella, Cristina
A1 Bousquet, Jean
A1 Breiteneder, Heimo
A1 Carvalho, Daniela
A1 De-Las-Vecillas, Leticia
A1 Diamant, Zuzana
A1 Eguiluz-Gracia, Ibon
A1 Eiwegger, Thomas
A1 Eyerich, Stefanie
A1 Fokkens, Wytske
A1 Gao, Ya-Dong
A1 Hannachi, Farah
A1 Johnston, Sebastian L
A1 Jutel, Marek
A1 Karavelia, Aspasia
A1 Klimek, Ludger
A1 Moya, Beatriz
A1 Nadeau, Kari C
A1 O'Hehir, Robyn
A1 O'Mahony, Liam
A1 Pfaar, Oliver
A1 Sanak, Marek
A1 Schwarze, Jürgen
A1 Sokolowska, Milena
A1 Torres, María J
A1 van-de-Veen, Willem
A1 van-Zelm, Menno C
A1 Wang, De Yun
A1 Zhang, Luo
A1 Jimenez-Saiz, Rodrigo
A1 Akdis, Cezmi A
K1 COVID-19
K1 SARS-CoV-2
K1 Allergy
K1 Coronavirus disease 2019
K1 Severe acute respiratory syndrome-related coronavirus 2
AB In December 2019, China reported the first cases of the coronavirus disease 2019 (COVID-19). This disease, caused by the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), has developed into a pandemic. To date, it has resulted in ~9 million confirmed cases and caused almost 500 000 related deaths worldwide. Unequivocally, the COVID-19 pandemic is the gravest health and socioeconomic crisis of our time. In this context, numerous questions have emerged in demand of basic scientific information and evidence-based medical advice on SARS-CoV-2 and COVID-19. Although the majority of the patients show a very mild, self-limiting viral respiratory disease, many clinical manifestations in severe patients are unique to COVID-19, such as severe lymphopenia and eosinopenia, extensive pneumonia, a "cytokine storm" leading to acute respiratory distress syndrome, endothelitis, thromboembolic complications, and multiorgan failure. The epidemiologic features of COVID-19 are distinctive and have changed throughout the pandemic. Vaccine and drug development studies and clinical trials are rapidly growing at an unprecedented speed. However, basic and clinical research on COVID-19-related topics should be based on more coordinated high-quality studies. This paper answers pressing questions, formulated by young clinicians and scientists, on SARS-CoV-2, COVID-19, and allergy, focusing on the following topics: virology, immunology, diagnosis, management of patients with allergic disease and asthma, treatment, clinical trials, drug discovery, vaccine development, and epidemiology. A total of 150 questions were answered by experts in the field providing a comprehensive and practical overview of COVID-19 and allergic disease.
PB John Wiley & Sons
YR 2020
FD 2020-06-20
LK http://hdl.handle.net/10668/15736
UL http://hdl.handle.net/10668/15736
LA en
NO Riggioni C, Comberiati P, Giovannini M, Agache I, Akdis M, Alves-Correia M, et al. A compendium answering 150 questions on COVID-19 and SARS-CoV-2. Allergy. 2020 Oct;75(10):2503-2541
NO NHMRC Senior Research Fellowship, Grant/Award Number: GNT1117687; Consejo Superior de Investigaciones Científicas, Grant/Award Number: IJCI-2016-27619; Instituto de Salud Carlos III, Grant/Award Number: JR19/0029
DS RISalud
RD Apr 11, 2025